Chester County News and Community Website
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), headquartered in West Chester, PA, is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. For more information, visit www.verrica.com.
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced a series of achievements and financial milestones for the first quarter ending March 31, 2024. The company’s strides in …
Verrica Pharmaceuticals Reports Growth and Innovation in First Quarter Financial Results Read More WEST CHESTER, PA — In a significant development for Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), the company announced its lead dermatological product, YCANTH™, has been granted New Chemical Entity (NCE) Status …
Verrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protection Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has achieved a significant milestone in its commercial strategy. The Centers for Medicare & Medicaid Services (CMS) has issued a permanent …
Verrica Pharmaceuticals Earns Key CMS Approval, Streamlining Access to Molluscum Contagiosum Treatment Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leader in dermatology therapeutics, announced a significant development in its ongoing research for innovative skin cancer treatments. The company confirmed …
Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced that it received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration (FDA). …
Verrica Pharmaceuticals Gains FDA Alignment for YCANTH’s Phase 3 Clinical Development Plan Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced this week that it has entered into an agreement with Walgreens Co. The deal will see YCANTH™, the first FDA-approved …
Verrica Pharmaceuticals Expands Distribution Network for YCANTH with Walgreens Partnership Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics provider, has shared promising top-line results from the Phase 3 trial of TO-208 for molluscum contagiosum (“molluscum”) …
Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan Read More